Therapy-enhancing glucan

• US 7,704,973 B2
• Filed: 07/16/2004
• Issued: 04/27/2010
• Est. Priority Date: 07/16/2003
• Status: Expired due to Fees

• Current Assignee: Biotec BetaGlucans AS (Lallemand Inc.), Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Original Assignee: Sloan-Kettering Institute For Cancer Research (Memorial Sloan-Kettering Cancer Center)
• Inventors: Cheung, Nai-Kong V.
• Primary Examiner(s): Jiang; Shaojia Anna
• Assistant Examiner(s): OLSON, ERIC
• Application Number:
  US10/565,484
• Publication Number:
  US 20060188506A1
• Time in Patent Office: 2,111 Days
• Field of Search: None
• US Class Current: 514/54
• CPC Class Codes: A61K 2039/55583 Polysaccharides
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 31/739 Lipopolysaccharides
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/39541 against normal tissues, cells
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: A61K 47/36 Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C08B 37/0024 beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof

Abstract

This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance, which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Claims

1. A composition comprising:

(a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the cancer is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin'"'"'s lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin'"'"'s lymphoma, and epidermoid carcinoma; and

(b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β

-glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β

-glucan comprises a β

-1,3 backbone and at least one β

-1,3 side chain of two or more glucose units linked to the backbone by a β

-1,6 glycosidic bonds.

2. The composition of claim 1, wherein the β

-glucan is isolated from yeast.

3. The composition of claim 1, wherein the β

-glucan is isolated from Saccharomyces Cerevisiae.

4. The composition of claim 1, wherein the β

-glucan has a molecular weight from about 10 kDa to about 350 kDa.

5. The composition of claim 1, wherein the antibody is a monoclonal antibody or a complement-activating antibody.

6. The composition of claim 1, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3.

7. The composition of claim 1, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.

8. A composition comprising:

(a) a composition comprising an antibody that binds to a cancer cell, and at least one pharmaceutically acceptable carrier, wherein the antibody binds to a cancer cell expressing an antigen selected from the group consisting of CD20, HER2, EGFR, GD2, and GD3; and

(b) an orally administered composition comprising at least one pharmaceutically acceptable carrier and a soluble β

-glucan in an amount effective to enhance the antitumor effect of said antibody, wherein the β

-glucan comprises a β

-1,3 backbone and at least one β

1,3 side chain of two or more glucose units linked to the backbone by a β

-1,6 glycosidic bond.

9. The composition of claim 8, wherein the β

-glucan is isolated from yeast.

10. The composition of claim 8, wherein the β

-glucan is isolated from Saccharomyces Cerevisiae.

11. The composition of claim 8, wherein the β

-glucan has a molecular weight from about 10 kDa to about 350 kDa.

12. The composition of claim 8, wherein the antibody is a monoclonal antibody or a complement-activating antibody.

13. The composition of claim 8, wherein the cancer cell is selected from the group consisting of neuroblastoma, melanoma, non-Hodgkin'"'"'s lymphoma, breast cancer, Epstein-Barr related lymphoma, Hodgkin'"'"'s lymphoma, and epidermoid carcinoma.

14. The composition of claim 8, wherein the antibody is further capable of activating an antibody dependent cell-mediated cytotoxicity response.